Search research articles
Contact Us
Filters
Showing results (121-130 of 135) with videos related to
Page
of 14
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
October 1, 2010
Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice
Marcel Kremer, Anja Henn, Cornelia Kolb, et al.
Cardiovascular Research
|
December 4, 2022
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis
Jun Li, Shaobo Hu, Henry W B Johnson, et al.
Human Molecular Genetics
|
September 12, 2012
NUB1 modulation of GSK3β reduces tau aggregation
Emma Richet, Amy M Pooler, Teresa Rodriguez, et al.
The Prostate
|
March 9, 2005
Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation
Ying Waeckerle-Men, Edith Uetz-von Allmen, Roger von Moos, et al.
Journal of Psychiatric Research
|
April 15, 2014
The effect of trauma-focused therapy on the altered T cell distribution in individuals with PTSD: evidence from a randomized controlled trial
Julia Morath, Hannah Gola, Annette Sommershof, et al.
Cancer Immunology, Immunotherapy : CII
|
April 14, 2006
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Ying Waeckerle-Men, Edith Uetz-von Allmen, Markus Fopp, et al.
Nature Communications
|
August 22, 2018
The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation
Annette Aichem, Samira Anders, Nicola Catone, et al.
Nature Communications
|
November 4, 2018
Author Correction: The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation
Annette Aichem, Samira Anders, Nicola Catone, et al.
EMBO Reports
|
October 4, 2018
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity
Michael Basler, Michelle M Lindstrom, Jacob J LaStant, et al.
Scientific Reports
|
March 22, 2023
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
Dennis Horvath, Nigel Temperton, Martin Mayora-Neto, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 135) with videos related to
Sort By:
Page
of 14
Journal of Immunology (Baltimore, Md. : 1950)
|
October 1, 2010
Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice
Marcel Kremer, Anja Henn, Cornelia Kolb, et al.
Cardiovascular Research
|
December 4, 2022
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis
Jun Li, Shaobo Hu, Henry W B Johnson, et al.
Human Molecular Genetics
|
September 12, 2012
NUB1 modulation of GSK3β reduces tau aggregation
Emma Richet, Amy M Pooler, Teresa Rodriguez, et al.
The Prostate
|
March 9, 2005
Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation
Ying Waeckerle-Men, Edith Uetz-von Allmen, Roger von Moos, et al.
Journal of Psychiatric Research
|
April 15, 2014
The effect of trauma-focused therapy on the altered T cell distribution in individuals with PTSD: evidence from a randomized controlled trial
Julia Morath, Hannah Gola, Annette Sommershof, et al.
Cancer Immunology, Immunotherapy : CII
|
April 14, 2006
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Ying Waeckerle-Men, Edith Uetz-von Allmen, Markus Fopp, et al.
Nature Communications
|
August 22, 2018
The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation
Annette Aichem, Samira Anders, Nicola Catone, et al.
Nature Communications
|
November 4, 2018
Author Correction: The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation
Annette Aichem, Samira Anders, Nicola Catone, et al.
EMBO Reports
|
October 4, 2018
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity
Michael Basler, Michelle M Lindstrom, Jacob J LaStant, et al.
Scientific Reports
|
March 22, 2023
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
Dennis Horvath, Nigel Temperton, Martin Mayora-Neto, et al.
Page
of 14